Haptoglobin-β chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer

被引：21

作者：

Saito, Seiichi ^{[1
]}

Murayama, Yasuko ^{[1
]}

Pan, Yuzhuo ^{[1
]}

Taima, Takenobu ^{[1
]}

Fujimura, Tsutomu ^{[2
,3
,4
,5
]}

Murayama, Kimie ^{[2
,3
,4
]}

Sadilek, Martin ^{[6
]}

Egawa, Shin ^{[7
]}

Ueno, Seiji ^{[1
]}

Ito, Akihiro ^{[1
]}

Ishidoya, Shigeto ^{[1
]}

Nakagawa, Haruo ^{[1
]}

Kato, Masanori ^{[1
]}

Satoh, Makoto ^{[8
]}

Endoh, Mareyuki ^{[9
]}

Arai, Yoichi ^{[1
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Urol, Aoba Ku, Sendai, Miyagi 980, Japan

[2] Pacific NW Res Inst, Seattle, WA USA

[3] Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA

[4] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA

[5] Juntendo Univ, Grad Sch Med, Div Prote & Biomol Sci, Biomed Res Ctr,Bunkyo Ku, Tokyo, Japan

[6] Univ Washington, Dept Chem, Seattle, WA 98195 USA

[7] Jikei Univ, Sch Med, Dept Urol, Minato Ku, Tokyo, Japan

[8] Sen En Hosp, Dept Urol, Tagajo, Miyagi, Japan

[9] Tohoku Univ, Grad Sch Med, Dept Pathol, Aoba Ku, Sendai, Miyagi 980, Japan

来源：

INTERNATIONAL JOURNAL OF CANCER | 2008年 / 123卷 / 03期

关键词：

prostate cancer; haptoglobin; serum marker; RM2;

D O I：

10.1002/ijc.23490

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In our previous study, monoclonal antibody RM2, established toward the glycosyl epitope, reflected grade of malignancy of prostate cancer cells whereas RM2 reactivity to benign glands was negative or weak. RM2 reactivity was also detected in stroma, suggesting the glycoprotein RM2 recognizes could be released into the bloodstream. Then, we explored RM2 reactivity to sera of early prostate cancer. We compared RM2 reactivity to sera between 62 patients with early prostate cancer and 43 subjects with benign prostatic disease, and examined RM2 reactivity before and after radical prostatectomy in 15 patients by Western blotting. We also examined RM2 reactivity to sera of the other urogenital cancers. RM2 reactivity was significantly enhanced on a serum glycoprotein with molecular mass similar to 40 kDa, hereby termed GPX, in the patients with early prostate cancer when compared with those with benign prostatic disease (p < 0.0001). Setting an appropriate cutoff level, RM2 reactivity to GPX for detection of prostate cancer had sensitivity of 87% and specificity of 84%, respectively. Furthermore, the level of RM2 reactivity significantly decreased after radical prostatectomy (p = 0.006). However, increased RM2 reactivity to GPX was also observed in the other urogenital cancers. The proteomics approach identified GPX as haptoglobin-beta chain and RM2 showed preferential reactivity toward haptoglobin-beta chain derived from prostate cancer when compared with polyclonal anti-haptoglobin antibody. Haptoglobin-beta chain defined by RM2 is a novel serum marker that may be useful for detection of early prostate cancer when coupled with prostate-specific antigen because it is not specific to prostate cancer. (C) 2008 Wiley-Liss, Inc.

引用

页码：633 / 640

页数：8

共 33 条

[11] Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy [J].